Device Trial Radar · NCT03903471
22G-ProCore vs 22G-Standard Needle in Diagnosis of Lymphadenopathy by EBUS-TBNA
Last checked: Nov 20, 2026Latest source record: Sep 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 8, 2022
Primary completion
Oct 8, 2023
Study completion Oct 8, 2023
Sponsor
- Lead sponsor
- Jiayuan SunAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 4, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to compare the performance of 22G-ProCore and 22G-Standard needle in diagnosis of mediastinal and hilar lymphadenopathy via EBUS-TBNA with the purpose to explore the optimal technique for obtaining diagnostic material.
Conditions
- Lymph Node Disease
Interventions
22G-ProCore Endobronchial Ultrasound NeedleDevice
EchoTip Procore® Endobronchial HD Ultrasound Biopsy Needle, COOK
22G-Standard Endobronchial Ultrasound NeedleDevice
EchoTip® Ultra Endobronchial High Definition Ultrasound Needle, COOK
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diagnostic yield of 22G-ProCore needleTime frame: up to 6 months
- Diagnostic yield of 22G-Standard needleTime frame: up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.